Zai Lab Ltd (ZLAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zai Lab Ltd (ZLAB) has a cash flow conversion efficiency ratio of -0.104x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-63.41 Million) by net assets ($607.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Zai Lab Ltd stock valuation for the company's overall valuation and market capitalisation.
Zai Lab Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Zai Lab Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zai Lab Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zai Lab Ltd ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Zai Lab Ltd to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Centrais Elétricas Brasileiras S.A. - Eletrobrás
NYSE:EBR-B
|
0.039x |
|
Academy Sports Outdoors Inc
NASDAQ:ASO
|
0.076x |
|
Electric Connector Technology Co Ltd
SHE:300679
|
0.050x |
|
Transmissora Aliança de Energia Elétrica S.A
SA:TAEE11
|
0.086x |
|
H B Fuller Company
NYSE:FUL
|
-0.002x |
|
The Marzetti Company
NASDAQ:MZTI
|
0.055x |
|
Shanxi Securities Co Ltd
SHE:002500
|
0.284x |
|
Henan Yuneng Holdings Co Ltd
SHE:001896
|
0.427x |
Annual Cash Flow Conversion Efficiency for Zai Lab Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Zai Lab Ltd from 2015 to 2025. View Zai Lab Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $715.50 Million | $-150.79 Million | -0.211x | +17.52% |
| 2024-12-31 | $840.90 Million | $-214.87 Million | -0.256x | -2.65% |
| 2023-12-31 | $796.12 Million | $-198.18 Million | -0.249x | +29.20% |
| 2022-12-31 | $1.05 Billion | $-367.64 Million | -0.352x | +11.66% |
| 2021-12-31 | $1.38 Billion | $-549.23 Million | -0.398x | -115.41% |
| 2020-12-31 | $1.17 Billion | $-216.06 Million | -0.185x | +71.50% |
| 2019-12-31 | $294.66 Million | $-191.01 Million | -0.648x | -66.87% |
| 2018-12-31 | $251.08 Million | $-97.54 Million | -0.388x | -182.25% |
| 2017-12-31 | $235.17 Million | $-32.37 Million | -0.138x | -122.06% |
| 2016-12-31 | $-51.55 Million | $-32.16 Million | 0.624x | -0.05% |
| 2015-12-31 | $-18.37 Million | $-11.46 Million | 0.624x | -- |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more